Cytosorbents Corp
About Cytosorbents Corp
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2018
- $22.5M
- Net income
- -$8.2M
- Total assets
- $44.2M
- Market cap
- $28.8M
- Gross margin
- 71.5%
- Operating margin
- -39.8%
- Net margin
- -22.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $37.1M
- Cost of revenue
- $10.6M
- Gross profit
- $26.5M
- Operating expenses
- $41.2M
- Operating income
- -$14.7M
- Income tax
- -$401.0K
- Net income
- -$8.2M
- EPS (basic)
- $-0.13
- EPS (diluted)
- $-0.13
Balance sheet
- Total assets
- $44.2M
- Current assets
- $20.6M
- Total liabilities
- $38.3M
- Current liabilities
- $9.7M
- Shareholders’ equity
- $5.9M
Cash flow
- Operating cash flow
- -$12.4M
- Investing cash flow
- -$415.0K
- Financing cash flow
- $9.3M
- Net cash flow
- -$3.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $28.8M
- EPS (diluted)
- $-0.13
- Shares outstanding
- 70.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 17, 2005
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $8.2M in FY2018.
- Revenue declined 14% from FY2021 to FY2025.
- Gross margin of 71.5%, net margin -22.1%.
- Trading 68% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cytosorbents Corp.
Write a review
News about Cytosorbents Corp
News & sentiment via Polygon.io
